Ascendis Pharma Reports Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 12, 2025
– Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA®
– Q3 2025 operating profit of €11.0 million
Read more at globenewswire.com
